Syngene International Limited — Updates, 23-07-2025: Press Release

Syngene delivered a strong start to the financial year. Revenue from operations grew 11% YoY to Rs 875 Cr, with EBITDA up 19% to Rs 224 Cr, achieving a 25% margin. Profit after tax surged 59% to Rs 87 Cr. This growth was largely driven by converting research service pilot programs into longer-term contracts. Operationally, the Bengaluru Biologics Unit III facility is now licensed and operating, with Rs 343.8 Cr in assets capitalized. Preparations are advancing for the US Bayview facility to commence operations later this year. A new dedicated peptide laboratory also expanded capabilities.